Industry
Technology Biotech
Ardelyx is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes first‑in‑class medicines for patients with significant unmet medical needs. Its approved products include IBSRELA, for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor for adults with chronic kidney disease on dialysis. The company is also advancing additional programs, including a Phase 3 trial for chronic idiopathic constipation and a next‑generation NHE3 inhibitor.
Audience tags

Sponsorship Goals

Ardelyx is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes first‑in‑class medicines for patients with significant unmet medical needs. Its approved products include IBSRELA, for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor for adults with chronic kidney disease on dialysis. The company is also advancing additional programs, including a Phase 3 trial for chronic idiopathic constipation and a next‑generation NHE3 inhibitor.

Sponsorship Goals

Sponsor Details

People
If you currently work at this organization, click the “Do you work here?” button to request editing privileges.
This SponsorPitch page is about Ardelyx and contains information about this organization's sponsorship activity, sponsorship decision makers and sponsorship preferences. This page is not endorsed by or affiliated with Ardelyx, though it may be actively managed and updated by company representatives. If you currently work at this organization, click the Do you work here button to request management privileges. All trademarks, service marks and copyrights are property of their respective owners.